AIM: To investigate the effect of oncolytic adenovirus SG600-IL24 and replication-incompetent adenovirus Ad.IL-24 on hepatocellular carcinoma (HCC) cell lines and normal liver cell line. METHODS: HCC cell lines (HepG2, Hep3B and MHCC97L) and normal liver cell line (L02) with a different p53 status were infected with SG600-IL24 and Ad.IL-24, respectively. Melanoma differentiation-associated (MDA)-7/interleukin (IL)-24 mRNA and protein expressions in infected cells were detected by reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and Western blotting, respectively. Apoptosis of HCC cells and normal liver cells was detected by cytometric assay with Hoechst33258 staining. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to investigate proliferation of HCC cells and normal liver cells, and cell cycle was assayed by flow cytometry. RESULTS: RT-PCR, ELISA and Western blotting showed that the exogenous MDA-7/IL-24 gene was highly expressed in cells infected with SG600-IL24. MTT indicated that SG600-IL24 could suppress the growth of HepG2, Hep3B, MHCC97L, with an inhibition rate of 75% ± 2.5%, 85% ± 2.0%, 72% ± 1.8%, respectively (P < 0.01), promote the apoptosis of HepG2, Hep3B, MHCC97L, with an apoptosis rate of 56.59% ± 4.0%, 78.36% ± 3.5%, 43.39% ± 2.5%, respectively (P < 0.01), and block the HCC cell lines in the G2/M phase with a blocking rate of 35.4% ± 4.2%, 47.3% ± 6.2%, 42% ± 5.0%, respectively (P < 0.01) but not the normal liver cell line in a p53-independent manner. CONCLUSION: SG600-IL24 can selectively suppress the proliferation and apoptosis of HCC cell lines in vitro but not normal liver cell line L02 in a p53-independent manner. Compared with Ad.IL-24, SG600-IL24 can significantly enhance the antitumor activity in HCC cell lines.
AIM: To investigate the effect of oncolytic adenovirus SG600-IL24 and replication-incompetent adenovirus Ad.IL-24 on hepatocellular carcinoma (HCC) cell lines and normal liver cell line. METHODS: HCC cell lines (HepG2, Hep3B and MHCC97L) and normal liver cell line (L02) with a different p53 status were infected with SG600-IL24 and Ad.IL-24, respectively. Melanoma differentiation-associated (MDA)-7/interleukin (IL)-24 mRNA and protein expressions in infected cells were detected by reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and Western blotting, respectively. Apoptosis of HCC cells and normal liver cells was detected by cytometric assay with Hoechst33258 staining. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to investigate proliferation of HCC cells and normal liver cells, and cell cycle was assayed by flow cytometry. RESULTS: RT-PCR, ELISA and Western blotting showed that the exogenous MDA-7/IL-24 gene was highly expressed in cells infected with SG600-IL24. MTT indicated that SG600-IL24 could suppress the growth of HepG2, Hep3B, MHCC97L, with an inhibition rate of 75% ± 2.5%, 85% ± 2.0%, 72% ± 1.8%, respectively (P < 0.01), promote the apoptosis of HepG2, Hep3B, MHCC97L, with an apoptosis rate of 56.59% ± 4.0%, 78.36% ± 3.5%, 43.39% ± 2.5%, respectively (P < 0.01), and block the HCC cell lines in the G2/M phase with a blocking rate of 35.4% ± 4.2%, 47.3% ± 6.2%, 42% ± 5.0%, respectively (P < 0.01) but not the normal liver cell line in a p53-independent manner. CONCLUSION: SG600-IL24 can selectively suppress the proliferation and apoptosis of HCC cell lines in vitro but not normal liver cell line L02 in a p53-independent manner. Compared with Ad.IL-24, SG600-IL24 can significantly enhance the antitumor activity in HCC cell lines.
Authors: Irina V Lebedeva; Zao-Zhong Su; Devanand Sarkar; Rahul V Gopalkrishnan; Samuel Waxman; Adly Yacoub; Paul Dent; Paul B Fisher Journal: Oncogene Date: 2005-01-20 Impact factor: 9.867
Authors: Adly Yacoub; Clint Mitchell; Young Hong; Rahul V Gopalkrishnan; Zhao-Zhong Su; Pankaj Gupta; Moria Sauane; Irina V Lebedeva; David T Curiel; Parameshwar J Mahasreshti; Myrna R Rosenfeld; William C Broaddus; C David James; Steven Grant; Paul B Fisher; Paul Dent Journal: Cancer Biol Ther Date: 2004-08-10 Impact factor: 4.742
Authors: Zi Lai Zhang; Wei Guo Zou; Chun Xia Luo; Bing Hua Li; Jin Hui Wang; Lan Ying Sun; Qi Jun Qian; Xin Yuan Liu Journal: Cell Res Date: 2003-12 Impact factor: 25.617
Authors: Irina V Lebedeva; Zao-Zhong Su; Devanand Sarkar; Shinichi Kitada; Paul Dent; Samuel Waxman; John C Reed; Paul B Fisher Journal: Cancer Res Date: 2003-12-01 Impact factor: 12.701
Authors: Margaret A Park; Teneille Walker; Aditi Pandya Martin; Jeremy Allegood; Nicollaq Vozhilla; Luni Emdad; Devanand Sarkar; Mohammed Rahmani; Martin Graf; Adly Yacoub; Costas Koumenis; Sarah Spiegel; David T Curiel; Christina Voelkel-Johnson; Steven Grant; Paul B Fisher; Paul Dent Journal: Mol Cancer Ther Date: 2009-05-05 Impact factor: 6.261
Authors: Swadesh K Das; Siddik Sarkar; Rupesh Dash; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2012 Impact factor: 6.242